Loading
EB-NK-301 is an experimental CAR-NK cell therapy from Beijing Biotech in phase 2 trials, aimed at TROP2.
EB-NK-301 is a CAR-NK cell therapy developed by Beijing Biotech. Its target is TROP2. ClinicalTrials.gov describes the intervention as: Investigational allogeneic CAR-NK cell product targeting TROP2, administered by intravenous infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT07589530, plans to enrol 60 participants with primary completion expected 2027-02-14. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
CAR-NK cell therapy directed at TROP2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to TROP2.
1.EB-NK-301 slips into a pocket on TROP2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"EB-NK-301" OR ABSTRACT:"EB-NK-301" OR TITLE:"TROP2-CAR NK" OR ABSTRACT:"TROP2-CAR NK") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EB-NK-301, not a curated reading list.
Shares TROP2 and the tag pipeline.
Shares TROP2 and the tag pipeline.
Shares TROP2 and the tag pipeline.
Shares CAR-NK & CAR-macrophage, TROP2.